A Phase 2a, Open-label, Dose Finding Study to Determine the Safety and Tolerability of SOTATERCEPT (ACE-011) in Adults With Beta (β)-Thalassemia
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs Sotatercept (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 18 Mar 2019 Planned End Date changed from 28 Feb 2020 to 30 Jul 2020.
- 04 Dec 2018 Results assessing safety of Sotatercept in thalassemia patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 14 May 2018 Planned End Date changed from 31 Dec 2024 to 28 Feb 2020.